At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

Two years ago, we published a list of 5 predictions about AI in the year 2030. The article sparked a lot of fascinating (and ...

For European start-ups, the past quarter has been the strongest in four years, with significant funding in the UK, Germany ...

Google will add SandboxAQ’s so-called large quantitative models to its cloud marketplace, allowing researchers to combine Google’s Gemini language models with AI systems trained on ...

Currently universities across Bangladesh seem to be locked in an exhausting, state-mandated ritual. Instead of refreshing the ...

Alphabet shares fell 5 percent, erasing 270 billion in value, after AI leaders Noam Shazeer joined OpenAI and John Jumper left Google DeepMind for Anthropic, spooking investors ...

The rise of AI in drug development is just beginning its journey to delivering treatments to patients.

Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...